eXoZymes Inc Dossier
Financial Snapshot
Revenue, profitability, returns, debt, and capital allocation
Revenue $0TTM through 30 Jun 2026
Net Income -$10.2MTTM through 30 Jun 2026
Free Cash Flow -$7.1MTTM through 30 Jun 2026
Margins
| Current |
|---|
Balance Sheet Health
Debt / Equity0.76x
Current Ratio1.32x
Net Debt-$279.7Knet cash position
Cash & Equivalents$5.7M
Quality Metrics
Altman Z-Score-0.34
Piotroski F-Score3 / 9
Multi-Year Trend
RevenueFY2023: $70.1K
Diluted EPS-$1.20TTMFY2025: $-1.09
Dividend
No dividend
Capital Allocation
R&D Spend$4.9M
Segment Performance
| Segment | Revenue | YoY | Outlook |
|---|---|---|---|
| SimplePath Platform | $0 | View detailsFocusing on commercialization milestones and technology transfer to external pilot plants. | |
| NCT Program | $0 | View detailsAchieved kilo-scale production and successful pilot scale-up with Cayman Chemical. Commercialization efforts are ongoing through the NCTx subsidiary. |
Filing Detail Members
This section is available to registered members. Create a free account or sign in to unlock the full breakdown.